Background: Females have a high prevalence of lower urinary tract symptoms (LUTS), ranging from 64% to 76%. The prevalence and severity of LUTS are higher in postmenopausal women due to low estrogen levels affecting genitourinary tissue. Tamsulosin is an uroselective α1A adrenergic receptor antagonist used for the treatment of benign prostatic hyperplasia, with proven efficacy and safety. It is also used off-label for the treatment of lower urinary tract symptoms in females. The present study aims to assess the safety and efficacy of Tamsulosin in the treatment of non-neurogenic lower urinary tract voiding symptoms in post-menopausal women. Methods: The present study is a prospective observational study conducted from February 2020 to July 2021 in the Department of Surgery and Urology at Shyam Shah Medical College, Rewa (M.P). After applying inclusion and exclusion criteria, 163 patients were selected for the study. Comprehensive clinical history, physical examinations, and relevant investigations were done. The International Prostate Symptom Score (IPSS) and IPSS Quality of Life index (IPSS-QOL) were also evaluated. After categorizing the patients into voiding and storage symptoms, including urinary incontinence, those with voiding dysfunction were prescribed 0.4 mg of Tamsulosin for 30 days and follow-up was planned on day 15 and day 30. During these follow-up visits, the response to the treatment was monitored by uroflowmetry, ultrasonography for post-void residual volume (PVR), IPSS score, and IPSS-QOL index. Results: The average age of postmenopausal females with LUTS in this study was 55.84 ± 9.37 years. The prevalence of LUTS was 44.15%. There was a significant change in International Prostate Symptom Score (IPSS) from 11.70±3.87 to 6.91±1.91, IPSS-Quality of Life (QOL) from 3.90±0.87 to 2.23±0.7, maximum flow rate (Qmax) from 12.73±3.79 to 14.66±2.86, and post-void residual (PVR) from 67.04±25.5 to 46.56±14.75 at the last follow-up. Adverse reactions were noted in 5.14% of patients, which resolved after discontinuation of medication. Conclusion: The study conclusively demonstrates that Tamsulosineffectively alleviates LUTS in post-menopausal women, significantly improving both objective measures and patient-reported outcomes. Overall, Tamsulosin was shown to be an effective therapy with a good safety profile for managing LUTS in post-menopausal women, contributing to improved urinary function and quality of life